Fiduciary Trust Co. reduced its stake in Shire PLC (NASDAQ:SHPG) by 30.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 823 shares of the biopharmaceutical company’s stock after selling 359 shares during the period. Fiduciary Trust Co.’s holdings in Shire PLC were worth $136,000 at the end of the most recent reporting period.
A number of other hedge funds also recently added to or reduced their stakes in SHPG. Hartford Financial Management Inc. raised its stake in Shire PLC by 5.4% in the second quarter. Hartford Financial Management Inc. now owns 621 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 32 shares in the last quarter. Thompson Davis & CO. Inc. raised its stake in Shire PLC by 3.1% in the first quarter. Thompson Davis & CO. Inc. now owns 640 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 19 shares in the last quarter. Pacer Advisors Inc. bought a new position in Shire PLC in the second quarter worth about $171,000. Stephens Inc. AR bought a new position in Shire PLC in the first quarter worth about $179,000. Finally, Quantbot Technologies LP bought a new position in Shire PLC in the first quarter worth about $182,000. 19.13% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “Fiduciary Trust Co. Decreases Position in Shire PLC (SHPG)” was originally reported by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://www.tickerreport.com/banking-finance/2888604/fiduciary-trust-co-decreases-position-in-shire-plc-shpg.html.
A number of brokerages have weighed in on SHPG. Piper Jaffray Companies set a $159.00 target price on shares of Shire PLC and gave the company a “hold” rating in a research note on Wednesday, July 26th. ValuEngine downgraded shares of Shire PLC from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. Zacks Investment Research downgraded shares of Shire PLC from a “hold” rating to a “sell” rating in a research note on Monday, July 17th. Sanford C. Bernstein downgraded shares of Shire PLC from an “outperform” rating to a “market perform” rating and decreased their target price for the company from $209.22 to $161.09 in a research note on Thursday, May 25th. Finally, BidaskClub downgraded shares of Shire PLC from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 5th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and fourteen have given a buy rating to the stock. Shire PLC currently has an average rating of “Buy” and a consensus price target of $220.08.
Shares of Shire PLC (NASDAQ SHPG) opened at 162.49 on Wednesday. Shire PLC has a one year low of $139.36 and a one year high of $209.22. The company has a 50-day moving average of $154.29 and a 200 day moving average of $169.27. The stock has a market cap of $48.40 billion, a PE ratio of 72.70 and a beta of 1.61.
Shire PLC (NASDAQ:SHPG) last released its quarterly earnings data on Friday, October 27th. The biopharmaceutical company reported $3.37 earnings per share for the quarter, missing the Zacks’ consensus estimate of $3.66 by ($0.29). Shire PLC had a return on equity of 14.10% and a net margin of 4.70%. On average, analysts predict that Shire PLC will post $14.93 earnings per share for the current year.
The firm also recently disclosed a semiannual dividend, which will be paid on Friday, October 20th. Stockholders of record on Friday, September 8th will be paid a $0.1527 dividend. The ex-dividend date is Thursday, September 7th. This represents a dividend yield of 0.21%. Shire PLC’s payout ratio is currently 41.07%.
Shire PLC Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.